Oppenheimer Starts Amarin Corporation (AMRN) at Underperform, $7 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Gilead Sciences (GILD) 'Quietly' Added Amarin's (AMRN) Vascepa to an Old NASH Combo Trial - Raymond James
November 19, 2019 5:38 PM ESTRaymond James analyst Steven Seedhouse highlighted that Gilead Sciences (NASDAQ: GILD) has "quietly" added Amarin's (NASDAQ: AMRN) Vascepa to an old NASH combo trial.
The analyst commented, "We recently noticed a change to the clinical... More
Amarin Corp. (AMRN) Declines After Shares Hit with 'Underperform' Rating
November 19, 2019 4:29 PM ESTAmarin Corp. (NASDAQ: AMRN) declined post-market-close Tuesday after the stock was initiated with an Underperform rating and a price target of $7 at Oppenheimer. The stock declined about 3.5%.
... More
